Complicated crosstalk between HMGA and non-coding RNAs modulates hallmarks of cancer

Cancer Cell International, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 7, 2025

High mobility group A1 (HMGA1) is a class of non-histone chromosomal protein and highly expressed in the embryonic period many tumors. It involved multiple hallmarks tumors affects occurrence progression Nowadays, non-coding RNAs (ncRNAs), such as miRNA, lncRNA, circRNA, have been found to play crucial role HMGA1 regulation. Moreover, some ncRNAs are reported be downstream effectors HMGA1. They interact with each other affect cancer targeting or may provide potential strategies for therapy. In this review, we give an overview recent studies describing crosstalk between oncogenic ncRNAs. We also point out impact interaction on biological behavior their tumor therapy order offer implications directions both basic science clinical applications.

Language: Английский

---

Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease management

Frontiers in Cardiovascular Medicine, Journal Year: 2025, Volume and Issue: 12

Published: March 20, 2025

RNA therapeutics are emerging as a promising approach for cardiovascular diseases (CVDs) management, offering targeted gene regulation through modalities like mRNA, siRNA, and miRNA. In recent years, researchers have conducted lot of research on the application technology in treatment CVDs. Despite hurdles off-target effects immune responses, clinical trial outcomes encouraging. This review synthesizes current progress CVDs, examining their mechanisms, advantages, challenges delivery safety. We highlight potential personalized medicine, combination artificial intelligence (AI) bioinformatics advancing therapeutics. The future CVDs is poised significant impact, necessitating continued interdisciplinary collaboration to optimize these treatments ensure patient safety efficacy.

Language: Английский

---

Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: unknown, P. 113641 - 113641

Published: March 1, 2025

Language: Английский

---

Diagnostic and Therapeutic Advances of RNAs in Precision Medicine of Gastrointestinal Tumors

Biomedicines, Journal Year: 2024, Volume and Issue: 13(1), P. 47 - 47

Published: Dec. 28, 2024

Gastrointestinal tumors present a significant challenge for precision medicine due to their complexity, necessitating the development of more specific diagnostic tools and therapeutic agents. Recent advances have positioned coding non-coding RNAs as emerging biomarkers these malignancies, detectable by liquid biopsies, innovative Many RNA-based therapeutics, such small interfering RNA (siRNA) antisense oligonucleotides (ASO), entered clinical trials or are available on market. This review provides narrative examination potential in gastrointestinal cancers, with an emphasis its application medicine. discusses current challenges, drug resistance tumor metastasis, highlights how molecules can be leveraged targeted detection treatment. Additionally, this categorizes targets based tissue type, offering comprehensive analysis role advancing tumors.

Language: Английский

---

The discovery of tiny RNAs that have crucial roles

Science China Life Sciences, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 28, 2024

Language: Английский

---

RNA Delivery Nanoparticles for Infectious Diseases

Materials chemistry horizons., Journal Year: 2024, Volume and Issue: 3(3), P. 1 - 14

Published: Dec. 1, 2024

Language: Английский

---